Literature DB >> 24508696

Uveal melanoma: A pathologist's perspective and review of translational developments.

Lynn Schoenfield1.   

Abstract

The eye and periorbital soft tissue are derived from the neuroectodermal neural crest, leading to a wide range of tumor types that arise at this site. The uveal tract (iris, ciliary body, and choroid) normally contains melanocytes, and thus both benign nevi and malignant melanoma can arise there, the choroid being the most frequent site. Uveal melanoma (UM) in adults and retinoblastoma (in young children) are the 2 most common primary intraocular malignancies. Retinoblastoma is the most common eye cancer worldwide, but the most common ocular cancer in the United States and Europe is UM. This review will focus on UM and will include the epidemiology, pathologic findings, prognosis and treatment, and review of ongoing molecular discoveries aimed at elucidating the pathways that could lead to adjuvant therapy. These tumors are not uncommon to dedicated ocular pathologists and may occasionally be encountered by general pathologists as well. First, a short word about metastases to the uveal tract is in order, because of its importance in the differential diagnosis. Although the most common primary malignancy in the adult eye is UM, the most frequent adult intraocular malignancy identified in autopsy studies is metastatic carcinoma to the uveal tract. Metastases usually occur late, and the eye is thus rarely enucleated in this setting. However it is important to be aware of this as sometimes, the ophthalmologist cannot determine clinically if an amelanotic tumor represents melanoma or metastasis, possibly from an unknown primary. Shields and colleagues reported on their experience and found that the most common primary sites for uveal metastasis are breast, followed by lung, and then the gastrointestinal tract. Immunohistochemical stains for cytokeratin or more specific markers such as CK7, CK20, TTF-1, BRST-2, CDX2, and PSA may be helpful if there is no known primary. Metastases to the eye also occur in the orbit, eyelid, and rarely to the retina.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24508696     DOI: 10.1097/PAP.0000000000000010

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  13 in total

1.  Amelanotic Irido-Ciliary Ring Melanoma: A Clinicopathological Correlation.

Authors:  Hassan A Aziz; Yasha S Modi; Thomas P Plesec; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2015-12-02

2.  Clinical presentation and management of uveal melanoma.

Authors:  Abelardo Rodríguez; Alfonso Dueñas-Gonzalez; Sarai Delgado-Pelayo
Journal:  Mol Clin Oncol       Date:  2016-09-27

3.  Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?

Authors:  João Lobo; Carla Pinto; Micaela Freitas; Manuela Pinheiro; Rámon Vizcaino; Esther Oliva; Manuel R Teixeira; Carmen Jerónimo; Carla Bartosch
Journal:  Virchows Arch       Date:  2016-12-03       Impact factor: 4.064

4.  Long noncoding RNA MALAT1 promotes uveal melanoma cell growth and invasion by silencing of miR-140.

Authors:  Lei Sun; Peng Sun; Qi-Ying Zhou; Xiangchun Gao; Qing Han
Journal:  Am J Transl Res       Date:  2016-09-15       Impact factor: 4.060

5.  An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma.

Authors:  Rhonda C Kines; Isabella Varsavsky; Sanghamitra Choudhary; Debaditya Bhattacharya; Sean Spring; Roger McLaughlin; Shin J Kang; Hans E Grossniklaus; Demetrios Vavvas; Stephen Monks; John R MacDougall; Elisabet de Los Pinos; John T Schiller
Journal:  Mol Cancer Ther       Date:  2017-12-14       Impact factor: 6.261

6.  Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Authors:  A Gordon Robertson; Juliann Shih; Christina Yau; Ewan A Gibb; Junna Oba; Karen L Mungall; Julian M Hess; Vladislav Uzunangelov; Vonn Walter; Ludmila Danilova; Tara M Lichtenberg; Melanie Kucherlapati; Patrick K Kimes; Ming Tang; Alexander Penson; Ozgun Babur; Rehan Akbani; Christopher A Bristow; Katherine A Hoadley; Lisa Iype; Matthew T Chang; Andrew D Cherniack; Christopher Benz; Gordon B Mills; Roel G W Verhaak; Klaus G Griewank; Ina Felau; Jean C Zenklusen; Jeffrey E Gershenwald; Lynn Schoenfield; Alexander J Lazar; Mohamed H Abdel-Rahman; Sergio Roman-Roman; Marc-Henri Stern; Colleen M Cebulla; Michelle D Williams; Martine J Jager; Sarah E Coupland; Bita Esmaeli; Cyriac Kandoth; Scott E Woodman
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

7.  Diagnostic value of SOX-10 immunohistochemical staining for the detection of uveal melanoma.

Authors:  Sarah A Alghamdi; Pablo Zoroquiain; Ana Beatriz T Dias; Sulaiman R Alhumaid; Sultan Aldrees; Miguel N Burnier
Journal:  Ecancermedicalscience       Date:  2015-08-20

Review 8.  MicroRNA dysregulation in uveal melanoma: a new player enters the game.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; Yang Jiang
Journal:  Oncotarget       Date:  2015-03-10

9.  Growth and Metastasis of Intraocular Tumors in Aged Mice.

Authors:  Zhiqiang Han; Joseph R Brown; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-05-01       Impact factor: 4.799

10.  Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma.

Authors:  Wei Dai; Jingfeng Zhou; Bei Jin; Jingxuan Pan
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.